Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer
1998

Matrix Metalloproteinases in Breast Cancer

Sample size: 84 publication Evidence: moderate

Author Information

Author(s): AG Remacdel, A Noel, C Duggan, E McDermott, N O'Higgins, JM Foidart, MJ Duffy

Primary Institution: University of Liège

Hypothesis

The study aims to measure different matrix metalloproteinases (MMPs) in extracts of both normal breast tissue and primary breast cancers and relate their levels to pathological characteristics and patient outcomes.

Conclusion

High levels of a previously unreported gelatinase, a 50-kDa band, were associated with improved overall survival in breast cancer patients.

Supporting Evidence

  • Patients with high levels of the 50-kDa gelatinase band had significantly better survival than those with low levels.
  • MMP-2 and MMP-9 levels were not significantly related to patient outcomes.
  • Most tumor samples showed gelatinase A in its activated form, which was not found in normal breast tissue.

Takeaway

The study looked at special proteins in breast cancer and found that one type, the 50-kDa band, might help patients live longer.

Methodology

Gelatin zymography and ELISA were used to measure levels of different MMPs in breast cancer and normal breast tissue samples.

Limitations

The study had a relatively small sample size and a short follow-up period of 25 months.

Participant Demographics

The study included 84 patients with primary breast cancers, with follow-up data available for 80 patients.

Statistical Information

P-Value

0.0014

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication